AI-generated from publicly available materials.Receptor.AI and Sethera are collaborating to develop an innovative closed-loop drug discovery workflow aimed at addressing challenging therapeutic targets.
The partnership will leverage Sethera's advanced platform, which enables the creation and experimental screening of diverse polymacrocyclic peptide libraries. This approach allows for the generation of unique peptide architectures, moving beyond traditional design methods that rely on fixed structural motifs. Receptor.AI will complement this by employing physics-based modeling and artificial intelligence to analyze various data points, including sequence and activity, thereby refining candidate selection and optimization processes.
The initial focus will be on a hard-to-drug target, with the goal of enhancing hit confirmation and lead optimization compared to conventional methods. This integrated workflow aims to create a robust feedback loop, where experimental results continuously inform subsequent cycles of design and testing. Both companies plan to retain their individual technologies while collaborating under a structured research framework that delineates responsibilities across experimental and computational domains.
This collaboration represents a significant advancement in the drug discovery landscape, as it seeks to establish a systematic, iterative approach to peptide lead development. By combining Sethera's unique peptide chemistry with Receptor.AI's computational insights, they aim to streamline the transition from experimental findings to validated therapeutic candidates, ultimately enhancing the efficiency and efficacy of drug discovery efforts.